NCT07348276BefejeződöttKorai 1. fázis

First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain

First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands ([18F]ABBV964i and [ 18F]ABBV-965i) as Potential PET Radioligands for Imaging Tau Protein in the Brain of Patients With Probable PSP and Healthy Volunteers

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. júl. 10.

Rövid összefoglaló (regiszter, angolul)

This clinical study is being conducted to learn more about two new imaging drugs, called \[18F\]ABBV-964i and \[18F\]ABBV-965i, which are designed to help doctors see changes in the brain related to a condition called Progressive Supranuclear Palsy (PSP). PSP is a rare disease that affects movement, balance, and thinking. These drugs are used with a type of scan called PET (Positron Emission Tomography) to show areas of the brain where a protein called tau builds up. Tau buildup is linked to PSP and other brain diseases. The main goal of this study is to find out if these imaging drugs are safe for people and if they work well to show tau in the brain. The study will also look at how the drugs move through the body and how much radiation they give off. Researchers hope this information will help develop better tools for diagnosing PSP and tracking how it changes over time. Who can join? Adults who are healthy or who have PSP may be able to take part. Participants will have screening tests to make sure they qualify. What does participation involve? People in the study will have PET scans, blood tests, and other safety checks. Some participants will also have an MRI scan. The study is divided into three parts: Part A checks radiation levels in healthy volunteers, Part B looks at how the drugs work in the brain of PSP patients and healthy volunteers, and Part C (optional) repeats scans to see if results are consistent. Why is this important? There is currently no cure for PSP, and better imaging tools could help researchers develop new treatments. By joining this study, participants will help advance research that may improve care for people with PSP and similar conditions in the future.

Állapot (regiszter): Befejeződött
Fázis (regiszter): Korai 1. fázis
Vizsgálattípus: Beavatkozással járó
Résztvevők száma: 11 (tényleges)
Első benyújtás: 2025. dec. 26.
Kezdés: 2025. nov. 17.
Elsődleges befejezés: 2026. márc. 19.
Fő szponzor: Invicro
NCT-szám: NCT07348276

Mit vállalsz

Vizsgálat típusa: Beavatkozással járó · Korai 1. fázis
Bevont résztvevők: 11
2025. nov. 17. és az elsődleges befejezés (2026. márc. 19.) között
1 helyszín, 1 országban
Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket

A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Korábbi kezelés

Investigational drug/device use within 30 days
MRI contraindications (implants, claustrophobia) for PSP participants
Major surgery or significant blood loss within 4 weeks

Más betegség

History of drug or alcohol abuse in past 12 months
Clinically significant lab abnormalities or unstable illness
Significant comorbid conditions (GI, CV, hepatic, renal, etc.)
Positive for Hepatitis B, Hepatitis C, or HIV

Egyéb

Pregnant, lactating, or breastfeeding
Abnormal clotting parameters (if arterial sampling)
Use of OTC meds or supplements within 2 weeks (healthy volunteers)
Use of anti-hemostasis meds within 2 weeks of arterial line placement for PSP participants
Unable to lie still for 90 minutes
Deemed unsuitable by Investigator

Kiket keres a vizsgálat

Males or females: PSP 40-80 years; HV 18-80 years
Body weight: 43-120 kg (95-265 lb)
Women of childbearing potential: abstinent or use 2 contraception methods (one barrier) during study and 30 days post last injection
Men: use 2 contraception methods and refrain from sperm donation during study and 90 days post last injection
Adequate circulation and normal clotting for arterial cannulation
Sufficient mobility and ability to lie still for imaging
Healthy Volunteers: informed consent, no clinically relevant findings, no cognitive impairment
PSP Participants: informed consent or assent with LAR consent, clinical diagnosis per NINDS-SPSP criteria, MRI consistent with PSP, able to ambulate, tolerate MRI, comply with study procedures, caregiver available if needed

Életkor a regiszterben: 18 év – 80 év · Nem: nők és férfiak · Egészséges önkénteseket is fogad

A teljes feltétellista: ClinicalTrials.gov

Helyszínek (1)

Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.

Helyszín	Város	Ország	Helyszín állapota
Invicro (dba Perceptive) Ennek a helyszínnek vagy a koordinátora? Erősítsd meg az állapotát	New Haven	Egyesült Államok	Ismeretlen állapot

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.